ReviewCancers2024
Embracing Personalized Strategies in Radiotherapy for Nasopharyngeal Carcinoma: Beyond the Conventional Bounds of Fields and Borders.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- A Dual GSH/ROS-Functional NIR Fluorescent Platform for Synergistic Photodynamic Therapy and Radiosensitization in Nasopharyngeal Carcinoma.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Complementary roles of GPU-accelerated Monte Carlo and ArcCHECK in TomoTherapy quality assurance.Physical and engineering sciences in medicine · 2026Article
- The clinical value of FAPI PET/CT in delineating target volumes for nasopharyngeal carcinoma.European journal of nuclear medicine and molecular imaging · 2025Article
- Targeting Ferroptosis in Nasopharyngeal Carcinoma: Mechanisms, Resistance, and Precision Therapeutic Opportunities.International journal of molecular sciences · 2025Review
- Article
- A global analysis of nasopharynx cancer burden attributable to occupational formaldehyde exposure.Frontiers in oncology · 2025Article
- Microbiota and metabolomic profiling coupled with machine learning to identify biomarkers and drug targets in nasopharyngeal carcinoma.Frontiers in pharmacology · 2025Article
- Individualization of clinical target volume delineation in eccentric nasopharyngeal carcinoma: a prospective comparative study.Frontiers in oncology · 2025Article
- Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival.JCO precision oncology · 2025Article
- Dose-guided individualized planning target volume margin optimization in nasopharyngeal carcinoma: a retrospective megavoltage computed tomography-based cumulative analysis.Frontiers in oncology · 2025Article
- A Combined Loss-driven Framework for Automated Parotid Segmentation in Head-and-Neck Computed Tomography.Journal of medical physicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is the primary treatment modality for non-metastatic nasopharyngeal carcinoma (NPC) across all TN-stages. Locoregional control rates have been impressive even from the 2D radiotherapy (RT) era, except when the ability to deliver optimal dose coverage to the tumor is compromised. However, short- and long-term complications following head and neck RT are potentially debilitating, and thus, there has been much research investigating technological advances in RT delivery over the past decades, with the primary goal of limiting normal tissue damage. On this note, with a plateau in gains of therapeutic ratio by modern RT techniques, future advances have to be focused on individualization of RT, both in terms of dose prescription and the delineation of target volumes. In this review, we analyzed the guidelines and evidence related to contouring methods, and dose prescription for early and locoregionally advanced (LA-) NPC. Next, with the preference for induction chemotherapy (IC) in patients with LA-NPC, we assessed the evidence concerning radiotherapy adaptations guided by IC response, as well as functional imaging and contour changes during treatment. Finally, we discussed on RT individualization that is guided by EBV DNA assessment, and its importance in the era of combinatorial immune checkpoint blockade therapy with RT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.